39 related articles for article (PubMed ID: 38635741)
1. When is the right time to initiate rehabilitation? Time will tell….
Greising SM; Call JA
Exp Physiol; 2024 Jun; 109(6):889-891. PubMed ID: 38493319
[No Abstract] [Full Text] [Related]
2. Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancer-a narrative review.
Huddy JR; Huddy FMS; Markar SR; Tucker O
Dis Esophagus; 2018 Jan; 31(1):1-11. PubMed ID: 29024949
[TBL] [Abstract][Full Text] [Related]
3. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Matsuda S; Takeuchi H; Kawakubo H; Ando N; Kitagawa Y
Ann Thorac Cardiovasc Surg; 2016 Oct; 22(5):275-283. PubMed ID: 27384595
[TBL] [Abstract][Full Text] [Related]
4. Protocol of a pilot randomized clinical trial to evaluate nutritional support and rehabilitation on prevention of skeletal muscle mass loss during neoadjuvant chemotherapy in patients with esophageal cancer.
Miki Y; Nishi S; Tamura T; Imai T; Nambara M; Fukuoka T; Yoshii M; Toyokawa T; Lee S; Fujii H; Yoshida H; Ikebuchi M; Maeda K
PLoS One; 2024; 19(4):e0302003. PubMed ID: 38635741
[TBL] [Abstract][Full Text] [Related]
5. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
6. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
9. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
[TBL] [Abstract][Full Text] [Related]
10. The Evaluation of Sarcopenia before Neoadjuvant Chemotherapy Is Important for Predicting Postoperative Pneumonia in Patients with Esophageal Cancer.
Nishi S; Miki Y; Imai T; Nambara M; Miyamoto H; Tamura T; Yoshii M; Toyokawa T; Tanaka H; Lee S; Maeda K
Dig Surg; 2023; 40(5):153-160. PubMed ID: 37497924
[TBL] [Abstract][Full Text] [Related]
11. Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108).
Imamura H; Matsuyama J; Nishikawa K; Endo S; Kawase T; Kimura Y; Fukui J; Kawada J; Kurokawa Y; Fujitani K; Sakai D; Kawakami H; Tsujinaka T; Shimokawa T; Matsubara Y; Satoh T; Furukawa H;
Ann Gastroenterol Surg; 2021 Nov; 5(6):776-784. PubMed ID: 34755009
[TBL] [Abstract][Full Text] [Related]
12. The Optimal Definition of Sarcopenia for Predicting Postoperative Pneumonia after Esophagectomy in Patients with Esophageal Cancer.
Nambara M; Miki Y; Tamura T; Yoshii M; Toyokawa T; Tanaka H; Lee S; Muguruma K; Shibata T; Ohira M
World J Surg; 2021 Oct; 45(10):3108-3118. PubMed ID: 34189621
[TBL] [Abstract][Full Text] [Related]
13. Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial.
Miyazaki Y; Omori T; Fujitani K; Fujita J; Kawabata R; Imamura H; Okada K; Moon JH; Hirao M; Matsuyama J; Saito T; Takahashi T; Kurokawa Y; Yamasaki M; Takiguchi S; Mori M; Doki Y;
Gastric Cancer; 2021 Sep; 24(5):1150-1159. PubMed ID: 33835329
[TBL] [Abstract][Full Text] [Related]
14. Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer.
Abraham M; Kordatou Z; Barriuso J; Lamarca A; Weaver JMJ; Cipriano C; Papaxoinis G; Backen A; Mansoor W
PLoS One; 2019; 14(11):e0224540. PubMed ID: 31774822
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.
Gallois C; Artru P; Lièvre A; Auclin E; Lecomte T; Locher C; Marthey L; Zaimi Y; Faroux R; Pernot S; Barret M; Taieb J
Eur J Cancer; 2019 Sep; 119():35-43. PubMed ID: 31415985
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
